Veradermics to Present Data on Oral Minoxidil Treatment for Hair Loss at AAD 2026

Event summary

  • Veradermics will present three abstracts at the 2026 AAD Annual Meeting, including data on VDPHL01's efficacy compared to existing minoxidil formulations.
  • One presentation will feature a blinded, retrospective investigator global assessment conducted by six independent dermatologists.
  • Two presentations will analyze social listening data on patient perceptions and experiences with current pattern hair loss treatments.
  • VDPHL01 is an extended-release oral minoxidil tablet in Phase 3 development for pattern hair loss in both men and women.

The big picture

Veradermics' presentations at the AAD 2026 Annual Meeting highlight the strategic importance of addressing the unmet needs in the pattern hair loss market, which affects 80 million people in the U.S. alone. The company's focus on developing an oral, non-hormonal treatment like VDPHL01 could potentially transform the aesthetics market, projected to reach $30 billion by 2028. The social listening data underscores the disconnect between patient and dermatologist perceptions, presenting an opportunity for Veradermics to differentiate its offering.

What we're watching

Clinical Validation
How the comparative efficacy data of VDPHL01 will position it against existing minoxidil formulations in the market.
Patient Adoption
Whether the social listening insights will translate into higher patient satisfaction and adherence to VDPHL01.
Regulatory Pathway
The pace at which Veradermics can navigate the FDA approval process for VDPHL01, given its Phase 3 status.